Inhibrx Biosciences

INHIBRX BIOSCIENCES INC

Inhibrx

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Titoli a dividendo scelti dai migliori analisti di Wall Street

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

APEI

INBX

OLED

Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying

Wall Street US stocks

HNRG

TCBI

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

Health care cost illustration

EXAS

TDOC

Top 4 Health Care Stocks That Are Preparing To Pump This Month

Inhibrx Biosciences Inc

Inhibrx Inc COM

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Earnings

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

AVRO

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp

Anika Therapeutics

Annexon

Cidara Therapeutics

Cardiff Oncology

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Foghorn Therapeutics

Genfit

Gossamer Bio

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Monopar Therapeutics

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

AVITA Medical

Rezolute

Tevogen Bio Holdings

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

JMP Securities

Credit Suisse

Evercore ISI Group

Comments

Inhibrx Biosciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga